ClinicalTrials.gg
CompletedNCT02348593Updated Jul 23, 2019Results posted

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"

A Phase 3 interventional study of JZP-110 and Placebo oral tablet in Narcolepsy, sponsored by Jazz Pharmaceuticals. Completed at 60 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-23.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.

Enrollment
2nd of 15
239 · median 120
Started
2015
with 2 others
Phase 3
8 of 18
1 open now
Registered
7th of 18
by date

Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 7th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Narcolepsy by Jazz Pharmaceuticals, or all of them as a file.
02

Study summary

This trial is a 12-week, randomized, double-blind, placebo controlled, multicenter, 4-treatment parallel group study of the safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy.

03

Conditions studied

  • Narcolepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. Males and females between 18 and 75 years of age, inclusive
  2. Diagnosis of narcolepsy according to ICSD-3 or criteria
  3. from 18 to \<45 kg/m2
  4. Consent to use a medically acceptable method of
  5. Willing and able to provide written

Major Exclusion Criteria:

  1. Female subjects who are pregnant, nursing, or lactating
  2. Moderate or severe sleep apnea on the baseline PSG.
  3. Any other medical, behavioral, or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness
  4. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria
  5. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator
  6. History of bariatric surgery within the past year or a history of any gastic bypass procedure
  7. Presence or history of significant cardiovascular disease
  8. Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness
  9. Use of any medications that could affect the evaluation of cataplexy
  10. Received an drug in the past 30 days or five half-lives (whichever is longer)
  11. Previous exposure to or participation in a previous clinical trial of JZP-110 (ADX-N05, R228060, YKP10A)
  12. History of phenylketonuria (PKU) or history of to phenylalanine-derived products
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
239 participants (actual)

Study arms

  • Active comparator
    75 mg of JZP-110

    Once Daily Dosing

    Drug: JZP-110

  • Active comparator
    150 mg JZP-110

    Once Daily Dosing

    Drug: JZP-110

  • Active comparator
    300 mg of JZP-110

    Once Daily Dosing

    Drug: JZP-110

  • Placebo comparator
    Placebo

    Once Daily Dosing

    Drug: Placebo oral tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12

    Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake; a positive change from baseline represents improvement in the sleep latency time. Mean sleep latency defined as the average of the first 4 MWT trials, if 3 or 4 of them are non-missing.

    Time frame: Baseline to Week 12

  2. Change in ESS Score From Baseline to Week 12

    Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12

    Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse

    Time frame: Baseline to Week 12

  2. Change in Sleep Latency Time on MWT Trial 1 at Week 12

    Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

    Time frame: Change from baseline for sleep latency in MWT during trial 1 at week 12

  3. Change in Sleep Latency Time on MWT Trial 2 at Week 12

    Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

    Time frame: Change from baseline for sleep latency in MWT during trial 2 at week 12

  4. Change in Sleep Latency Time on MWT Trial 3 at Week 12

    Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

    Time frame: Change from baseline for sleep latency in MWT during trial 3 at week 12

  5. Change in Sleep Latency Time on MWT Trial 4 at Week 12

    Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

    Time frame: Change from baseline for sleep latency in MWT during trial 4 at week 12

  6. Change in Sleep Latency Time on MWT Trial 5 at Week 12

    Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

    Time frame: Change from baseline for sleep latency in MWT during trial 5 at week 12

  7. Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-Minute MWT From Baseline to Week 4

    Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from Baseline to Week 4.

    Time frame: Baseline to Week 4

07

Results

Posted Jul 23, 2019

Participant flow

Participant flow — Overall Study
Milestone75 mg of JZP-110150 mg JZP-110300 mg of JZP-110Placebo
Started59595959
Completed49514352
Not completed108167

Outcome measures

PrimaryChange in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12

Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicating greater ability to stay awake; a positive change from baseline represents improvement in the sleep latency time. Mean sleep latency defined as the average of the first 4 MWT trials, if 3 or 4 of them are non-missing.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · minutes
Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12
minutesPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 122.12 ± 1.2894.74 ± 1.3359.77 ± 1.32712.27 ± 1.389
PrimaryChange in ESS Score From Baseline to Week 12

Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · points on a scale
Change in ESS Score From Baseline to Week 12
points on a scalePlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Change in ESS Score From Baseline to Week 12-1.6 ± 0.65-3.8 ± 0.67-5.4 ± 0.66-6.4 ± 0.68
SecondarySubjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12

Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of subjects
Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12
percentage of subjectsPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 1239.767.878.284.7
SecondaryChange in Sleep Latency Time on MWT Trial 1 at Week 12

Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

Time frame:
Change from baseline for sleep latency in MWT during trial 1 at week 12
Reported as:
Least squares mean · minutes
Change in Sleep Latency Time on MWT Trial 1 at Week 12
minutesPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Change in Sleep Latency Time on MWT Trial 1 at Week 12-0.55 ± 4.6583.27 ± 1.7259.87 ± 1.7139.91 ± 1.841
SecondaryChange in Sleep Latency Time on MWT Trial 2 at Week 12

Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

Time frame:
Change from baseline for sleep latency in MWT during trial 2 at week 12
Reported as:
Least squares mean · minutes
Change in Sleep Latency Time on MWT Trial 2 at Week 12
minutesPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Change in Sleep Latency Time on MWT Trial 2 at Week 121.41 ± 1.6385.70 ± 1.6979.46 ± 1.67414.50 ± 1.835
SecondaryChange in Sleep Latency Time on MWT Trial 3 at Week 12

Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

Time frame:
Change from baseline for sleep latency in MWT during trial 3 at week 12
Reported as:
Least squares mean · minutes
Change in Sleep Latency Time on MWT Trial 3 at Week 12
minutesPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Change in Sleep Latency Time on MWT Trial 3 at Week 123.79 ± 1.7996.35 ± 1.90811.31 ± 1.85913.99 ± 1.996
SecondaryChange in Sleep Latency Time on MWT Trial 4 at Week 12

Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

Time frame:
Change from baseline for sleep latency in MWT during trial 4 at week 12
Reported as:
Least squares mean · minutes
Change in Sleep Latency Time on MWT Trial 4 at Week 12
minutesPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Change in Sleep Latency Time on MWT Trial 4 at Week 122.33 ± 1.5793.77 ± 1.6639.77 ± 1.60613.50 ± 1.734
SecondaryChange in Sleep Latency Time on MWT Trial 5 at Week 12

Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at Week 12.

Time frame:
Change from baseline for sleep latency in MWT during trial 5 at week 12
Reported as:
Least squares mean · minutes
Change in Sleep Latency Time on MWT Trial 5 at Week 12
minutesPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Change in Sleep Latency Time on MWT Trial 5 at Week 123.09 ± 1.8083.92 ± 1.9289.25 ± 1.88812.20 ± 1.969
SecondaryChange in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-Minute MWT From Baseline to Week 4

Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from Baseline to Week 4.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · minutes
Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-Minute MWT From Baseline to Week 4
minutesPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-Minute MWT From Baseline to Week 42.16 ± 1.2024.67 ± 1.2239.15 ± 1.24613.07 ± 1.211

Adverse events

Collected over Through Week 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/59 (0%)0/59 (0%)17/59 (28.8%)
75 mg of JZP-1100/59 (0%)0/59 (0%)19/59 (32.2%)
150 mg JZP-1100/59 (0%)1/59 (1.7%)32/59 (54.2%)
300 mg of JZP-1100/59 (0%)0/59 (0%)36/59 (61%)
Most frequent serious events
Most frequent serious events
EventPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
Non-cardiac chest painGeneral disorders0/590/591/590/59
AnxietyPsychiatric disorders0/590/591/590/59
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo75 mg of JZP-110150 mg JZP-110300 mg of JZP-110
HeadacheNervous system disorders3/596/5914/5918/59
Decreased appetiteMetabolism and nutrition disorders1/595/595/599/59
NasopharyngitisInfections and infestations3/595/598/593/59
NauseaGastrointestinal disorders1/593/596/596/59
Dry mouthGastrointestinal disorders2/593/594/596/59
AnxietyPsychiatric disorders1/591/593/595/59
Heart rate increasedInvestigations0/590/590/594/59
Upper respiratory tract infectionInfections and infestations1/591/594/590/59
Weight decreasedInvestigations0/591/591/593/59
Weight increasedInvestigations3/592/590/591/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)75 mg of JZP-110150 mg JZP-110300 mg of JZP-110PlaceboTotal
Mean36.5 ± 12.7838.1 ± 13.0034.3 ± 11.5136.0 ± 15.1736.3 ± 12.47
Sex: Female, Male
Sex: Female, Male(Participants)75 mg of JZP-110150 mg JZP-110300 mg of JZP-110PlaceboTotal
Female37424035154
Male2217192482
Race (NIH/OMB)
Race (NIH/OMB)(Participants)75 mg of JZP-110150 mg JZP-110300 mg of JZP-110PlaceboTotal
American Indian or Alaska Native01102
Asian03306
Native Hawaiian or Other Pacific Islander00101
Black or African American12651033
White46484847189
More than one race11125
Unknown or Not Reported00000
08

Study locations

60 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
  • Pulmonary Associates
    Glendale, Arizona 85306, United States
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • So Cal Institute For Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Pacific Sleep Medicine
    Oceanside, California 92054, United States
  • SDS Clinical Trials
    Orange, California 92868, United States
  • Stanford University Center for Narcolepsy
    Redwood City, California 94063, United States
  • Pacific Research Network, Inc.
    San Diego, California 92103, United States
  • Critical Care Pulmonary & Sleep Associates, LLC
    Lakewood, Colorado 80228, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Clinical Research Group of St. Petersburg
    Saint Petersburg, Florida 33707, United States
  • Florida Pediatric Research Institute
    Winter Park, Florida 32789, United States
  • Emory Sleep Center
    Atlanta, Georgia 30329, United States
  • NeuroTrials
    Atlanta, Georgia 30342, United States
  • SleepMed of Central Georgia
    Macon, Georgia 31201, United States
  • Northwestern University, Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Illinois Chicago, College of Nursing
    Chicago, Illinois 60612, United States
  • Veritas Clinical Specialties LTD
    Topeka, Kansas 66606, United States
  • Kentucky Research Group
    Louisville, Kentucky 40218, United States
  • The Center for Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Neurocare, Inc.
    Newton, Massachusetts 24590, United States
  • Clinical Neurophysiology Services
    Sterling Heights, Michigan 48314, United States
  • Minnesota Lung Center
    Edina, Minnesota 55435, United States
  • University of Missouri
    Columbia, Missouri 65201, United States
  • Clayton Sleep Institute
    Saint Louis, Missouri 63143, United States
  • Montefiore Medical center
    Bronx, New York 10467, United States
  • New York University Medical center
    New York, New York 10016, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Hickory Research Center
    Hickory, North Carolina 28602, United States
  • Hickory Research Center, ARSM Research, LLC
    Huntersville, North Carolina 28078, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607, United States
  • North Coast Clinical Trials Inc.
    Beachwood, Ohio 44122, United States
  • Sleep Management Institute
    Cincinnati, Ohio 45245, United States
  • Southwest Cleveland Sleep Research Center
    Cleveland, Ohio 44130, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio Sleep Medicine & Neuroscience Institute
    Dublin, Ohio 43017, United States
  • Mercy St. Anne & Mercy St. Charles Sleep Disorders Center
    Toledo, Ohio 43606, United States
  • Lowcountry Lung Critical Care
    Charleston, South Carolina 29406, United States
  • Sleep Med of South Carolina
    Columbia, South Carolina 29201, United States
  • FutureSearch Trials of Neurology LP
    Austin, Texas 78731, United States
  • Todd J. Swick
    Houston, Texas 77063, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Toronto Sleep Institute
    Toronto, Ontario M4P 1P2, Canada
  • Toronto Psychiatric Research Foundation
    Toronto, Ontario M5K 2A7, Canada
  • Pediatric Sleep Research Inc.
    Toronto, Ontario M6J 3S3, Canada
  • CARSM Sleep Laboratory & Clinic
    Montreal, Quebec H4J 1C5, Canada
  • Helsinki Sleep Clinic
    Helsinki, 00420, Finland
  • Hospital Roger Salengro
    Lille, 59000, France
  • Universite Paris 5 Hôtel-Dieu
    Paris, 75004, France
  • Hopital Bichat - Claude Bernard
    Paris, 75018, France
  • medbo Bezirksklinikum Regensburg Schlafmedizinisches Zentrum
    Regensburg, Bayern 93053, Germany
  • Universitaetsklinikum Muenster
    Muenster, North Rhine-Westphalia 48149, Germany
  • Advanced Sleep Research GmbH
    Berlin, 10117, Germany
  • Studienzentrum Wilhelmshoehe
    Kassel, 34131, Germany
  • Somni bene GmbH Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH
    Schwerin, 19053, Germany
  • Sleep Wake Center SEIN Heemstede
    Heemstede, Noord Holland 2103 SW, Netherlands
09

References and documents

Publications

  • Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. J Clin Sleep Med. 2022 Jan 1;18(1):235-244. doi: 10.5664/jcsm.9550. PubMed 34283019 ↗
  • Rosenberg R, Baladi M, Bron M. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021 Apr 1;17(4):711-717. doi: 10.5664/jcsm.9006. Erratum In: J Clin Sleep Med. 2021 Nov 1;17(11):2343. doi: 10.5664/jcsm.9596. PubMed 33226332 ↗
  • Dauvilliers Y, Shapiro C, Mayer G, Lammers GJ, Emsellem H, Plazzi G, Chen D, Carter LP, Lee L, Black J, Thorpy MJ. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial. CNS Drugs. 2020 Jul;34(7):773-784. doi: 10.1007/s40263-020-00744-2. PubMed 32588401 ↗
  • Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G, Chen D, Carter LP, Villa KF, Lee L, Menno D, Black J, Dauvilliers Y. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. Sleep Med. 2020 Mar;67:128-136. doi: 10.1016/j.sleep.2019.11.1250. Epub 2019 Dec 4. PubMed 31926465 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Feb 2017, 21 months.

Results were first posted in Jul 2019, 2 years 5 months after primary completion. A results delay was requested in Jan 2018.

Of 14 phase 3 interventional studies under Narcolepsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2015
First posted
Jan 28, 2015
StartActual
May 2015
Primary completionActual
Feb 2017
CompletionActual
Feb 2017
Results delay requested
Jan 19, 2018
Results first posted
Jul 23, 2019
Last update
Jul 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02348593
Responsible party
Sponsor
First posted
Jan 28, 2015
Start date
May 2015
Primary completion
Feb 2017
Completion
Feb 2017
Results posted
Jul 23, 2019
Last update
Jul 23, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion